The future of cognitive medicine lies in predictive biomarkers, blood- and physiology-based indicators that can presage cognitive decline before symptoms emerge. NeuroTrax digital cognitive testing has been at the forefront of integrating these biomarkers into research and clinical assessment.

In studies of older adults with cardiovascular disease, NeuroTrax assessments revealed that plasma lipids and apolipoproteins predict accelerated cognitive decline nearly two decades later. Specifically, higher Apo-B and LDL-C levels were linked to greater declines in memory and visual spatial function, highlighting the potential of lipid biomarkers to indicate risk for later-life cognitive impairment [1].

Serum uric acid (UA), a natural antioxidant, has also been investigated using NeuroTrax assessments. Lower UA levels were associated with poorer global cognition, memory, and executive function a decade later, highlighting the connection between oxidative stress, vascular burden, and cognitive outcomes [2].

Additionally, cerebrovascular reactivity (CVR) measured by transcranial doppler as a physiological biomarker has been shown to correlate with executive function and global cognitive performance. Impaired CVR, especially in the presence of carotid large-vessel disease, predicted reduced cognitive scores across multiple domains, emphasizing the importance of microvascular health in maintaining brain function [3].

NeuroTrax’s platform allows researchers to combine digital cognitive assessments with biomarker data seamlessly, creating a comprehensive view of brain health. By capturing subtle changes in cognitive function alongside blood and vascular indicators, NeuroTrax facilitates early risk identification and supports precision interventions tailored to individual patients.

As biomarker research expands, the integration of these measures (e.g., p-tau217 for Alzheimer’s disease) with standardized digital cognitive testing promises more accurate prediction and monitoring of brain health. NeuroTrax enables this next-generation approach, bridging the gap between lab-based biomarkers and clinically actionable insights.

Ready to complement your biomarker metrics with objective digital cognitive outcomes? Contact NeuroTrax today.

References:

[1] Lutski, M., Weinstein, G., Goldbourt, U., and Tanne, D. (2019). Plasma lipids, apolipoproteins, and subsequent cognitive decline in men with coronary heart disease. Journal of Alzheimer’s Disease, 67, 827–837. PMID: 30664505

[2] Molshatzki, N., Weinstein, G., Streifler, J.Y., Goldbourt, U., and Tanne, D. (2015). Serum uric acid and subsequent cognitive performance in patients with pre-existing cardiovascular disease. PloS One, 10: e0120862. PMID: 25794156

Stroke is a leading cause of long-term disability, often leaving patients with persistent physical and cognitive impairments. Yet new evidence shows that hyperbaric oxygen therapy (HBOT) can help restore function even long after the initial injury. A recent case study demonstrates how HBOT enabled remarkable recovery in a 45-year-old post-stroke patient, including improvement in cognitive function documented by NeuroTrax digital testing.

The patient, 15 months post-hemorrhagic stroke, presented with right-sided weakness, impaired gait, and cognitive deficits. After completing 83 HBOT sessions (2.0 ATA, 90 minutes each), the outcomes were extraordinary:

Clinical improvements:

• Regained independent walking with a quadruped cane
• Noticeable gains in strength, balance and coordination
• Improved speech fluency and articulation

Cognitive improvements (on NeuroTrax):

• +31.2% in verbal memory
• +10.7% in information processing speed
• +8.6% in attention

Imaging confirmation:

• Diffusion tensor imaging (DTI) revealed increased white matter integrity
• SPECT scans showed enhanced perfusion (+15.9%) in motor and frontal regions, aligning with improved mobility and cognition

This case highlights HBOT’s ability to actuate neuroplasticity and metabolic recovery in viable brain tissue. Additionally, NeuroTrax testing provided objective, quantifiable evidence of cognitive restoration, in line with the functional and imaging changes.

In another case study of a 62-year-old fibromyalgia patient treated with 60 HBOT sessions, NeuroTrax testing captured a 10% improvement in global cognition and a 26.9% gain in attention, supported by imaging that showed enhanced white matter integrity and brain perfusion. In addition to illustrating the versatility and efficacy of HBOT, these cases demonstrate the utility of NeuroTrax in characterizing and quantifying HBOT-related cognitive recovery.

For clinicians, the integration of NeuroTrax with advanced therapies like HBOT offers a powerful, evidence-based framework for tracking and optimizing neurorehabilitation outcomes.

Contact us to learn how NeuroTrax can bring objective, data-driven insights to your clinical practice.

Full text (open access):

https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-025-05453-2

Citations:

Khairy, S., Mouzayan, G., Wang, Z., Qureshi, U., Zaitoun, R., and Efrati, S. (2025). Anatomical and metabolic brain imaging correlation of neurological improvements following hyperbaric oxygen therapy—post-stroke recovery: A case report. Journal of Medical Case Reports, 19:493. PMID: 41068989

Mouzayan, G., Khairy, S., Wang, Z., Qureshi, U., Zaitoun, R., and Efrati, S. (2025). Efficacy of hyperbaric oxygen therapy in treating fibromyalgia linked to childhood trauma after late-onset and over a decade of symptoms: A case report. Journal of Medical Case Reports, 19:386. PMID: 40765001